Gallbladder cancer: A morphological and molecular update

Histopathology

Volumn 55, Issue 2, 2009, Pages 218-229

  Goldin, Robert David ^a   Roa, Juan Carlos ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSIDAD DE LA FRONTERA   (Chile)

Author keywords

Dysplasia; Gallbladder carcinoma; Molecular pathology

Indexed keywords

ALPHA CATENIN; BETA CATENIN; CA 125 ANTIGEN; CA 242 ANTIGEN; CYCLOOXYGENASE 2; FRAGILE HISTIDINE TRIAD PROTEIN; GEMCITABINE; HEPARANASE; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; PLAKOGLOBIN; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; SMAD4 PROTEIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UVOMORULIN; VASCULOTROPIN;

ADENOMA; ANOMALOUS PANCREATOBILIARY DUCTAL JUNCTION; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CHILE; CHOLECYSTECTOMY; CHOLECYSTITIS; CHROMOSOME 13Q; CHROMOSOME 18Q; CHROMOSOME 5Q; CHROMOSOME 8P; CONGENITAL MALFORMATION; DIET; DNA METHYLATION; DYSPLASIA; ENVIRONMENTAL FACTOR; GALLBLADDER CANCER; GALLBLADDER DISEASE; GALLSTONE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; INDIA; METAPLASIA; MICROSATELLITE INSTABILITY; MUTATION RATE; OBESITY; ONCOGENE C ERB; ONCOGENE K RAS; POLLUTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SEX ROLE;

ADENOCARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GALLBLADDER NEOPLASMS; GALLSTONES; GENES, ERBB-2; GENES, P16; GENES, P53; GENES, RAS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MUTATION; P21-ACTIVATED KINASES; PANCREATIC DUCTS; PRACTICE GUIDELINES AS TOPIC; SEX FACTORS;

EID: 68749104995     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03192.x     Document Type: Review

References (139)

1. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int. J. Cancer 2006 118 1591 1602.
2. Medina E, Kaempffer AM. [Cancer mortality in Chile: epidemiological considerations]. Rev. Med. Chil. 2001 129 1195 1202.
3. Lazcano-Ponce EC, Miquel JF, Munoz N et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J. Clin. 2001 51 349 364.
4. Roa I, Araya JC, Wistuba I, Villaseca M, de Aretxabala X, Burgos L. [Gallbladder cancer in the IX Region of Chile. Impact of the anatomopathological study of 474 cases]. Rev. Med. Chil. 1994 122 1248 1256.
5. Hsing AW, Gao YT, Han TQ et al. Gallstones and the risk of biliary tract cancer: a population-based study in China. Br. J. Cancer 2007 97 1577 1582.
6. Tazuma S, Kajiyama G. Carcinogenesis of malignant lesions of the gall bladder. The impact of chronic inflammation and gallstones. Langenbecks Arch. Surg. 2001 386 224 229.
7. Hsing AW, Bai Y, Andreotti G et al. Family history of gallstones and the risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Int. J. Cancer 2007 121 832 838.
8. Vitetta L, Sali A, Little P, Mrazek L. Gallstones and gall bladder carcinoma. Aust. NZ J. Surg. 2000 70 667 673.
9. Roa I, Ibacache G, Roa J, Araya J, de Aretxabala X, Munoz S. Gallstones and gallbladder cancer-volume and weight of gallstones are associated with gallbladder cancer: a case-control study. J. Surg. Oncol. 2006 93 624 628.
10. Csendes A, Becerra M, Rojas J, Medina E. Number and size of stones in patients with asymptomatic and symptomatic gallstones and gallbladder carcinoma: a prospective study of 592 cases. J. Gastrointest. Surg. 2000 4 481 485.
11. Mano H, Roa I, Araya JC et al. Comparison of mutagenic activity of bile between Chilean and Japanese female patients having cholelithiasis. Mutat. Res. 1996 371 73 77.
12. Larsson SC, Wolk A. Obesity and the risk of gallbladder cancer: a meta-analysis. Br. J. Cancer 2007 96 1457 1461. (Pubitemid 46685777)
13. Matsuba T, Qiu D, Kurosawa M et al. Overview of epidemiology of bile duct and gallbladder cancer focusing on the JACC Study. J. Epidemiol. 2005 15 (Suppl. 2 S150 S156.
14. Pandey M. Environmental pollutants in gallbladder carcinogenesis. J. Surg. Oncol. 2006 93 640 643.
15. Shukla PJ, Barreto SG, Gupta P et al. Is there a role for estrogen and progesterone receptors in gall bladder cancer? HPB (Oxford) 2007 9 285 288.
16. Nath G, Singh H, Shukla VK. Chronic typhoid carriage and carcinoma of the gallbladder. Eur. J. Cancer Prev. 1997 6 557 559.
17. Dutta U, Garg PK, Kumar R, Tandon RK. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am. J. Gastroenterol. 2000 95 784 787.
18. Kumar S, Kumar S, Kumar S. Infection as a risk factor for gallbladder cancer. J. Surg. Oncol. 2006 93 633 639.
19. Leong RW, Sung JJ. Review article: Helicobacter species and hepatobiliary diseases. Aliment. Pharmacol. Ther. 2002 16 1037 1045.
20. Silva CP, Pereira-Lima JC, Oliveira AG et al. Association of the presence of Helicobacter in gallbladder tissue with cholelithiasis and cholecystitis. J. Clin. Microbiol. 2003 41 5615 5618.
21. Fukuda K, Kuroki T, Tajima Y et al. Comparative analysis of Helicobacter DNAs and biliary pathology in patients with and without hepatobiliary cancer. Carcinogenesis 2002 23 1927 1931.
22. Fox JG, Dewhirst FE, Shen Z et al. Hepatic Helicobacter species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. Gastroenterology 1998 114 755 763.
23. Germain M, Martin E, Gremillet C Porcelain gallbladder and cancer (author's transl) Sem. Hop. 1979 55 1629 1632.
24. Stephen AE, Berger DL. Carcinoma in the porcelain gallbladder: a relationship revisited. Surgery 2001 129 699 703.
25. Towfigh S, McFadden DW, Cortina GR et al. Porcelain gallbladder is not associated with gallbladder carcinoma. Am. Surg. 2001 67 7 10.
26. Sasatomi E, Tokunaga O, Miyazaki K. Precancerous conditions of gallbladder carcinoma: overview of histopathologic characteristics and molecular genetic findings. J. Hepatobiliary Pancreat. Surg. 2000 7 556 567.
27. Kang CM, Kim KS, Choi JS, Lee WJ, Kim BR. Gallbladder carcinoma associated with anomalous pancreaticobiliary duct junction. Can J Gastroenterol 2007 21 383 387.
28. Chao TC, Wang CS, Jan YY, Chen HM, Chen MF. Carcinogenesis in the biliary system associated with APDJ. J. Hepatobiliary Pancreat. Surg. 1999 6 218 222.
29. Duarte I, Llanos O, Domke H, Harz C, Valdivieso V. Metaplasia and precursor lesions of gallbladder carcinoma. Frequency, distribution, and probability of detection in routine histologic samples. Cancer 1993 72 1878 1884.
30. Jarvi O, K Lauren P. Intestinal metaplasia in the mucosa of the gallbladder and common bile duct with additional observations on pancreas heterotopy. Ann. Med. Exp. Biol. Fenn. 1967 45 213 223.
31. Roa I, Araya JC, Villaseca M et al. Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression. Gastroenterology 1996 111 232 236.
32. Roa I, Araya JC, Wistuba I et al. Epithelial lesions associated with gallbladder carcinoma. A methodical study of 32 cases Rev. Med. Chil. 1993 121 21 29.
33. Yamamoto M, Nakajo S, Tahara E. Dysplasia of the gallbladder. Its histogenesis and correlation to gallbladder adenocarcinoma. Pathol. Res. Pract. 1989 185 454 460. (Pubitemid 20010247)
34. Yamamoto M, Nakajo S, Tahara E. Carcinoma of the gallbladder: the correlation between histogenesis and prognosis. Virchows Arch. A Pathol. Anat. Histopathol. 1989 414 83 90. (Pubitemid 19045942)
35. Yamagiwa H, Tomiyama H Significance of dysplasia of the gallbladder Rinsho Byori 1986 34 328 332.
36. Wistuba II, Albores-Saavedra J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J. Hepatobiliary Pancreat. Surg. 1999 6 237 244.
37. Roa I, de Aretxabala X, Morgan R et al. Clinicopathological features of gallbladder polyps and adenomas Rev. Med. Chil. 2004 132 673 679.
38. Kozuka S, Tsubone N, Yasui A, Hachisuka K. Relation of adenoma to carcinoma in the gallbladder. Cancer 1982 50 2226 2234.
39. Roa I, de Aretxabala X, Araya JC, Villaseca M, Roa J, Guzman P Incipient gallbladder carcinoma. Clinical and pathological study and prognosis in 196 cases Rev. Med. Chil. 2001 129 1113 1120.
40. Roa I, de Aretxabala X, Araya JC et al. Morphological prognostic elements in gallbladder cancer Rev. Med. Chil. 2002 130 387 395.
41. Yokoyama N, Watanabe H, Ajioka Y et al. Genetic alterations in gallbladder carcinoma: a review Nippon Geka Gakkai Zasshi 1998 99 687 695.
42. Wistuba II, Miquel JF, Gazdar AF, Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum. Pathol. 1999 30 21 25.
43. Roa I, Araya JC, Villaseca M, Roa J, de Aretxabala X, Ibacache G. Gallbladder cancer in a high risk area: morphological features and spread patterns. Hepatogastroenterology 1999 46 1540 1546.
44. Roa I, Araya JC, Wistuba I, de Aretxabala X Gallbladder cancer: anatomic and anatomo-pathologic considerations Rev. Med. Chil. 1990 118 572 579.
45. Frena A, Marinello P, La Guardia G, Martin F Incidental gallbladder carcinoma Chir. Ital. 2007 59 185 190.
46. Bazoua G, Hamza N, Lazim T. Do we need histology for a normal-looking gallbladder? J. Hepatobiliary Pancreat. Surg. 2007 14 564 568.
47. Roa I, Araya JC, de Aretxabala X, Salinas C, Wistuba I Gallbladder pathology in Temuco, IX Region Rev. Med. Chil. 1989 117 889 894.
48. Taylor HW, Huang JK. 'Routine' pathological examination of the gallbladder is a futile exercise. Br. J. Surg. 1998 85 208.
49. The Royal College of Pathologists. Histopathology and cytopathology of limited or no clinical value. Pathologists TRC, 2nd edn. London : The Royal College of Pathologists, 2005. Available at: http://www.rcpath.org/resources/ pdf/HOLNCV-2ndEdition.pdf.
50. Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J. Hepatol. 2008 48 598 605.
51. Nuzzo G, Clemente G, Cadeddu F, Ardito F, Ricci R, Vecchio FM. Papillary carcinoma of the gallbladder and anomalous pancreatico-biliary junction. Report of three cases and review of the literature. Hepatogastroenterology 2005 52 1034 1038.
52. Cangemi V, Fiori E, Picchi C et al. Early gallbladder carcinoma: a single-center experience. Tumori 2006 92 487 490.
53. Lada PE, Taborda B, Sanchez M et al. Adenosquamous and squamous carcinoma of the gallbladder Cir. Esp. 2007 81 202 206.
54. Mingoli A, Brachini G, Petroni R et al. Squamous and adenosquamous cell carcinomas of the gallbladder. J. Exp. Clin. Cancer Res. 2005 24 143 150.
55. Anjaneyulu V, Shankar-Swarnalatha G, Rao SC. Carcinoid tumor of the gall bladder. Ann. Diagn. Pathol. 2007 11 113 116.
56. Park JK, Choi SH, Lee S, Min KO, Yun SS, Jeon HM. Malignant gastrointestinal stromal tumor of the gallbladder. J. Korean Med. Sci. 2004 19 763 767.
57. Fujii H, Aotake T, Horiuchi T, Chiba Y, Imamura Y, Tanaka K. Small cell carcinoma of the gallbladder: a case report and review of 53 cases in the literature. Hepatogastroenterology 2001 48 1588 1593. (Pubitemid 34003483)
58. Pavithran K, Doval DC, Vaid AK, Verma RN. Small cell carcinoma of the gall bladder: case report and review of literature. Trop. Gastroenterol. 2001 22 170 171.
59. Roa I, de Aretxabala X, Araya JC et al. Findings in surgical reinterventions for cancer of the gallbladder in patients with and without preoperative chemotherapy and radiotherapy Rev. Med. Chil. 2001 129 1013 1020.
60. de Aretxabala XA, Roa IS, Burgos LA, Araya JC, Villaseca MA, Silva JA. Curative resection in potentially resectable tumours of the gallbladder. Eur. J. Surg. 1997 163 419 426.
61. de Aretxabala X, Losada H, Mora J et al. Neoadjuvant chemoradiotherapy in gallbladder cancer Rev. Med. Chil. 2004 132 51 57.
62. Goetze TO, Paolucci V. Immediate re-resection of T1 incidental gallbladder carcinomas: a survival analysis of the German Registry. Surg. Endosc. 2008 22 2462 2465.
63. Yildirim E, Celen O, Gulben K, Berberoglu U. The surgical management of incidental gallbladder carcinoma. Eur. J. Surg. Oncol. 2005 31 45 52.
64. Shirai Y, Yoshida K, Tsukada K, Muto T, Watanabe H. Radical surgery for gallbladder carcinoma. Long-term results. Ann. Surg. 1992 216 565 568.
65. Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J. Gastrointest. Surg. 2007 11 671 681.
66. de Aretxabala X, Roa I, Burgos L. Gallbladder cancer, management of early tumors. Hepatogastroenterology 1999 46 1547 1551.
67. de Aretxabala X, Roa I, Burgos L et al. Gallbladder cancer: an analysis of a series of 139 patients with restricted to the subserosal layer. J. Gastrointest. Surg. 2006 10 186 192.
68. Chan SY, Poon RT, Lo CM, Ng KK, Fan ST. Management of carcinoma of the gallbladder: a single-institution experience in 16 years. J. Surg. Oncol. 2008 97 68 74.
69. Pawlik TM, Gleisner AL, Vigano L et al. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J. Gastrointest. Surg. 2007 11 1478 1486 discussion 1486-1487.
70. Hou CS, Xu Z, Zhang TL et al. Prognostic analysis of T1 and T2 stage gallbladder cancer with invasion within the gallbladder wall Zhonghua Wai Ke Za Zhi 2006 44 1620 1623.
71. Goetze TO, Paolucci V. Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma: analysis of the German registry. Ann. Surg. 2008 247 104 108.
72. Iyer RV, Gibbs J, Kuvshinoff B et al. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann. Surg. Oncol. 2007 14 3202 3209.
73. Meyerhardt JA, Zhu AX, Stuart K et al. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig. Dis. Sci. 2008 53 564 570.
74. Julka PK, Puri T, Rath GK. A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma. Hepatobiliary Pancreat. Dis. Int. 2006 5 110 114.
75. de Aretxabala X, Roa I, Berrios M et al. Chemoradiotherapy in gallbladder cancer. J. Surg. Oncol. 2006 93 699 704.
76. Wright BE, Lee CC, Iddings DM, Kavanagh M, Bilchik AJ. Management of T2 gallbladder cancer: are practice patterns consistent with national recommendations? Am. J. Surg. 2007 194 820 825, discussion 825-826.
77. Kayahara M, Nagakawa T. Recent trends of gallbladder cancer in Japan: an analysis of 4,770 patients. Cancer 2007 110 572 580.
78. Kapoor VK. Advanced gallbladder cancer: Indian "middle path". J. Hepatobiliary Pancreat. Surg. 2007 14 366 373.
79. Wistuba II, Tang M, Maitra A et al. Genome-wide allelotyping analysis reveals multiple sites of allelic loss in gallbladder carcinoma. Cancer Res. 2001 61 3795 3800.
80. Rashid A. Cellular and molecular biology of biliary tract cancers. Surg. Oncol. Clin. N. Am. 2002 11 995 1009.
81. Masuhara S, Kasuya K, Aoki T, Yoshimatsu A, Tsuchida A, Koyanagi Y. Relation between K-ras codon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction. J. Hepatobiliary Pancreat. Surg. 2000 7 198 205.
82. Itoi T, Watanabe H, Ajioka Y et al. APC, K-ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis. Pathol. Int. 1996 46 333 340.
83. Ajiki T, Fujimori T, Onoyama H et al. K-ras gene mutation in gall bladder carcinomas and dysplasia. Gut 1996 38 426 429.
84. Ito R, Tamura K, Ashida H et al. Usefulness of K-ras gene mutation at codon 12 in bile for diagnosing biliary strictures. Int. J. Oncol. 1998 12 1019 1023.
85. Imai M, Hoshi T, Ogawa K. K-ras codon 12 mutations in biliary tract tumors detected by polymerase chain reaction denaturing gradient gel electrophoresis. Cancer 1994 73 2727 2733.
86. Kim YT, Kim J, Jang YH et al. Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett. 2001 169 59 68. (Pubitemid 32532097)
87. Hanada K, Tsuchida A, Iwao T et al. Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am. J. Gastroenterol. 1999 94 1638 1642.
88. Nakayama K, Konno M, Kanzaki A et al. Allelotype analysis of gallbladder carcinoma associated with anomalous junction of pancreaticobiliary duct. Cancer Lett. 2001 166 135 141.
89. Hanada K, Tsuchida A, Kajiyama G. Cellular kinetics and gene mutations in gallbladder mucosa with an anomalous junction of pancreaticobiliary duct. J. Hepatobiliary Pancreat. Surg. 1999 6 223 228.
90. Billo P, Marchegiani C, Capella C, Sessa F Expression of p53 in gallbladder carcinoma and in dysplastic and metaplastic lesions of the surrounding mucosa Pathologica 2000 92 249 256.
91. Takada M, Horita Y, Okuda S et al. Genetic analysis of xanthogranulomatous cholecystitis: of gallbladder cancer? Hepatogastroenterology 2002 49 935 937.
92. Roa I, Melo A, Roa J, Araya J, Villaseca M, de Aretxabala X P53 gene mutation in gallbladder cancer Rev. Med. Chil. 2000 128 251 258.
93. Quan ZW, Wu K, Wang J, Shi W, Zhang Z, Merrell RC. Association of p53, p16, and vascular endothelial growth factor expressions with the prognosis and metastasis of gallbladder. J. Am. Coll. Surg. 2001 193 380 383.
94. Yokoyama N, Hitomi J, Watanabe H et al. Mutations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile. Cancer Epidemiol. Biomarkers Prev. 1998 7 297 301.
95. Puhalla H, Wrba F, Kandioler D et al. Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer. Anticancer Res. 2007 27 1679 1684.
96. Roa JC, Vo Q, Araya JC et al. Inactivation of CDKN2A gene (p16) in gallbladder carcinoma Rev. Med. Chil. 2004 132 1369 1376.
97. Quan ZW, Wu K, Wang J, Shi W, Zhang Z, Merrell RC. Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J. Am. Coll. Surg. 2001 193 380 383.
98. Shi YZ, Hui AM, Li X, Takayama T, Makuuchi M. Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of p16INK4 protein in gallbladder carcinomas. Clin. Cancer Res. 2000 6 4096 4100.
99. Han JA, Kim JI, Ongusaha PP et al. P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J. 2002 21 5635 5644.
100. Asano T, Shoda J, Ueda T et al. Expressions of cyclooxygenase-2 and prostaglandin E-receptors in the gallbladder: crucial role of arachidonate metabolism in growth and progression. Clin. Cancer Res. 2002 8 1157 1167.
101. Legan M, Luzar B, Marolt VF, Cor A. Expression of cyclooxygenase-2 is associated with p53 premalignant and malignant gallbladder lesions. World J. Gastroenterol. 2006 12 3425 3429.
102. Zhi YH, Liu RS, Song MM et al. Cyclooxygenase-2 promotes angiogenesis by increasing vascular growth factor and predicts prognosis in gallbladder carcinoma. World J. Gastroenterol. 2005 11 3724 3728.
103. Legan M, Luzar B, Ferlan-Marolt V, Cor A. Cyclooxygenase-2 expression determines neo-angiogenesis in gallbladder carcinomas. Bosn. J. Basic Med. Sci. 2006 6 58 63.
104. Roa JC, Roa I, Correa P et al. Microsatellite instability in preneoplastic and neoplastic gallbladder. J. Gastroenterol. 2005 40 79 86.
105. Saetta AA. K-ras, p53 mutations, and microsatellite instability (MSI) in cancer. J. Surg. Oncol. 2006 93 644 649.
106. Kohya N, Miyazaki K, Matsukura S et al. Deficient expression of O(6)-methylguanine-DNA methyltransferase with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. Ann. Surg. Oncol. 2002 9 371 379.
107. Rashid A. Cellular and molecular biology of biliary tract cancers. Surg. Oncol. Clin. N. Am. 2002 11 995 1009.
108. Saetta A, Koilakou SV, Michalopoulos NV, Davaris PS. Evaluation of BAT-26 as an indicator of microsatellite instability in gallbladder carcinomas. Hepatogastroenterology 2003 50 1799 1802.
109. Tian Y, Ding RY, Zhi YH, Guo RX, Wu SD. Analysis of p53 and vascular endothelial growth factor gallbladder carcinoma for the determination of tumor. World J. Gastroenterol. 2006 12 415 419.
110. Tian Y, Ding RY, Zhi YH, Guo RX, Wu SD. Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. World J Gastroenterol 2006 12 415 419.
111. Giatromanolaki A, Sivridis E, Simopoulos C et al. Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas. J. Surg. Oncol. 2006 94 242 247.
112. Giatromanolaki A, Sivridis E, Koukourakis MI, Polychronidis A, Simopoulos C. Prognostic role of angiogenesis in operable carcinoma of the gallbladder. Am. J. Clin. Oncol. 2002 25 38 41.
113. Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk possible role of nitric oxide in carcinogenesis. Mutat. Res. 1994 305 253 264.
114. Zhang M, Pan JW, Ren TR, Zhu YF, Han YJ, Kuhnel W. Correlated expression of inducible nitric oxide synthase and benign and malignant diseased gallbladder. Ann. Anat. 2003 185 549 554.
115. Koda M, Yashima K, Kawaguchi K et al. Expression of Fhit, Mlh1, and P53 protein in human gallbladder. Cancer Lett. 2003 199 131 138.
116. Luzar B, Poljak M, Cor A, Klopcic U, Ferlan-Marolt V. Expression of human telomerase catalytic protein in gallbladder carcinogenesis. J. Clin. Pathol. 2005 58 820 825.
117. Niiyama H, Mizumoto K, Kusumoto M et al. Activation of telomerase and its diagnostic application in specimens from biliary tract neoplasms. Cancer 1999 85 2138 2143.
118. Itoi T, Shinohara Y, Takeda K et al. Detection of telomerase activity in biopsy specimens for diagnosis of biliary tract cancers. Gastrointest. Endosc. 2000 52 380 386.
119. Kim YW, Huh SH, Park YK, Yoon TY, Lee SM, Hong SH. Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol. Rep. 2001 8 1127 1132.
120. Kamel D, Paakko P, Nuorva K, Vahakangas K, Soini Y. p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. J. Pathol. 1993 170 67 72.
121. Roa I, Ibacache G, Melo A et al. Subserous gallbladder carcinoma: expression of cadherine-catenine complex Rev. Med. Chil. 2002 130 1349 1357.
122. Yanagisawa N, Mikami T, Saegusa M, Okayasu I. More frequent beta-catenin exon 3 mutations in gallbladder adenomas than in carcinomas indicate different lineages. Cancer Res. 2001 61 19 22.
123. Chang HJ, Jee CD, Kim WH. Mutation and altered expression of beta-catenin during gallbladder carcinogenesis. Am. J. Surg. Pathol. 2002 26 758 766.
124. Choi YL, Xuan YH, Shin YK et al. An immunohistochemical study of the expression of adhesion gallbladder lesions. J. Histochem. Cytochem. 2004 52 591 601.
125. Tang DG, Honn KV. Adhesion molecules and tumor metastasis: an update. Invasion Metastasis 1994 14 109 122.
126. Dowaki S, Kijima H, Kashiwagi H et al. CEA immunohistochemical localization is correlated with growth and metastasis of human gallbladder carcinoma. Int. J. Oncol. 2000 16 49 53.
127. Kanthan R, Radhi JM, Kanthan SC. Gallbladder carcinomas: an immunoprognostic evaluation of P53, Bcl-2, CEA and alpha-fetoprotein. Can. J. Gastroenterol. 2000 14 181 184.
128. Roa JC, Anabalon L, Roa I et al. Promoter methylation profile in gallbladder cancer. J. Gastroenterol. 2006 41 269 275.
129. Riquelme E, Tang M, Baez S et al. Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma. Cancer Lett. 2007 250 100 106.
130. Wistuba II, Ashfaq R, Maitra A, Alvarez H, Riquelme E, Gazdar AF. Fragile histidine triad gene abnormalities in the pathogenesis gallbladder carcinoma. Am. J. Pathol. 2002 160 2073 2079.
131. Kuroki T, Tajima Y, Matsuo K, Kanematsu T. Genetic alterations in gallbladder carcinoma. Surg. Today 2005 35 101 105.
132. Shukla VK, Singh G, Sharma D, Dixit VK, Singh U. Diagnostic value of serum CA242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder. Trop. Gastroenterol. 2006 27 160 165.
133. Wu W, Pan C, Yu H, Gong H, Wang Y. Heparanase expression in gallbladder carcinoma and its correlation to prognosis. J. Gastroenterol. Hepatol. 2008 23 491 497.
134. Pandey SN, Dixit M, Choudhuri G, Mittal B. Lipoprotein receptor associated protein (LRPAP1) insertion/deletion polymorphism: association with gallbladder cancer susceptibility. Int. J. Gastrointest. Cancer 2006 37 124 128. (Pubitemid 351642214)
135. Pandey SN, Modi DR, Choudhuri G, Mittall B. Slow acetylator genotype of N-acetyl transferase2 (NAT2) is associated with increased susceptibility to gallbladder cancer: the cancer risk not modulated by gallstone disease. Cancer Biol. Ther. 2007 6 91 96.
136. Pandey SN, Srivastava A, Dixit M, Choudhuri G, Mittal B. Haplotype analysis of signal peptide (insertion/deletion) and XbaI polymorphisms of the APOB gene in gallbladder cancer. Liver Int. 2007 27 1008 1015.
137. Tsuchiya Y, Kiyohara C, Sato T, Nakamura K, Kimura A, Yamamoto M. Polymorphisms of cytochrome P450 1A1, glutathione S-transferase class mu, and tumour protein p53 genes and the risk of developing gallbladder cancer in Japanese. Clin. Biochem. 2007 40 881 886.
138. Pandey SN, Jain M, Nigam P, Choudhuri G, Mittal B. Genetic polymorphisms in GSTM1, GSTT1, GSTP1, GSTM3 and the susceptibility to gallbladder cancer in North India. Biomarkers 2006 11 250 261.
139. Jiao X, Huang J, Wu S et al. hOGG1 Ser326Cys polymorphism and susceptibility to gallbladder cancer in a Chinese population. Int. J. Cancer 2007 121 501 505.